Want to join the conversation?
Biotechnology company $BIIB said it has appointed Michel Vounatsos as EVP and Chief Commercial Officer effective April 18, 2016. Mr. Vounatsos will oversee the development and execution of $BIIB's global commercial strategy and he will report to CEO George Scangos. Mr. Vounatsos comes to $BIIB from Merck where he held various leadership positions.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?